Description
Biosulin R Pharmacodynamics
Short-acting insulin. It is human insulin produced using recombinant DNA technology.
It interacts with specific receptor of outer cytoplasmic cell membrane and forms insulin-receptor complex, which stimulates intracellular processes, including synthesis of several key enzymes (including hexokinase, pyruvate kinase, glycogen synthetase). Decrease of glucose content in blood is caused by increase of its intracellular transport, intensification of absorption and assimilation by tissues, stimulation of lipogenesis, glycogenogenesis, decrease of glucose production rate by liver.
The duration of action of insulin preparations is mainly due to the rate of absorption, which depends on several factors (e.g., dose, route and site of administration), and therefore the action profile of insulin is subject to considerable variation, both in different people and in the same patient.
After p / n injection, the onset of action of the drug is observed after about 30 min, the maximum effect – between 2 and 4 h, the duration of action – 6-8 h.
Indications
– diabetes mellitus;
– Emergency conditions in patients with diabetes mellitus, accompanied by decompensation of carbohydrate metabolism.
Contraindications
– hypoglycemia;
– Hypersensitivity to insulin or other components of the drug.
Dosage and administration method.
The drug dose is determined by the physician individually, in each case on the basis of blood glucose levels.
The drug is intended for p / n, i / m, i / v administration.
The average daily dose is from 0.5 to 1 IU/kg of body weight (depends on the individual characteristics of the patient and the blood glucose level).
The drug is administered 30 min before a meal or snack containing carbohydrates.
The temperature of injected insulin should correspond to room temperature.
In monotherapy the administration frequency is 3 (if necessary – 5-6 times/). If the daily dose exceeds 0.6 IU/kg, it must be administered as 2 or more injections in different areas of the body.
Biosulin® P is usually injected by p/k into the anterior abdominal wall. Injections may also be given into the thigh, buttock, or deltoid region of the shoulder. It is necessary to change the injection sites within the anatomical area to prevent the development of lipodystrophy.
Biosulin® P should be administered intravenously and intravenously only under the control of a physician.
Biosulin® P is a short-acting insulin and is usually used in combination with a medium-acting insulin (Biosulin® H)
